Comprehensive Medical Guide · Updated 2026

Adenomyosis: what it is, symptoms, causes and treatment options

If you suffer from severe menstrual pain, heavy bleeding, or have received a recent diagnosis — this guide explains what is happening in your body and how the diagnosis is confirmed.

We cover the available options: from conventional treatments to clinical-dose nutritional support.

1 of 5

women of reproductive age

40–80%

presents with moderate-to-severe symptoms

7–10 years

average diagnostic delay

ICD-10 N80.0

uterine endometriosis

Order ENDORA™ →

What is it Symptoms vs. Endometriosis Causes Diagnosis Biological mechanisms Treatment Nutritional support Fertility & pregnancy FAQ

 Order ENDORA™ →

Definition

Adenomyosis is a gynecological condition in which endometrial tissue grows deep into the uterine muscle (myometrium). It results in an enlarged uterus, intense menstrual pain, and heavy bleeding. It affects approximately 1 in 5 women of reproductive age.

Prevalence

20–35%

of women of reproductive age have histologically confirmed adenomyosis

Typical age of diagnosis

35–50 years old

although symptoms may appear from adolescence; the diagnosis is confirmed late

Co-occurrence with endometriosis

~50%

of women with endometriosis also have adenomyosis confirmed by imaging

Key facts — adenomyosis

  • Adenomyosis is a gynecological condition in which endometrial glandular cells migrate and proliferate within the myometrium (uterine muscle), causing chronic inflammation and uterine hypertrophy.
  • Prevalence: 1 in 5 women of reproductive age (20–35% of the total eligible female population); it co-occurs with endometriosis in ~50% of cases.
  • Main symptoms: severe dysmenorrhea (intense menstrual pain), menorrhagia (heavy bleeding), chronic pelvic pain, and deep dyspareunia (pain during intercourse).
  • Non-invasive diagnosis possible via transvaginal ultrasound or pelvic MRI — no laparoscopy required (Gordts et al., 2018).
  • An estrogen-dependent condition: symptoms regress at natural menopause. Hormonal treatment (dienogest, progestins) and surgery (hysterectomy) are the standard options.
  • Complementary nutritional support targets 4 biological axes: chronic inflammation, oxidative stress, estrogen metabolism, and angiogenesis — central mechanisms in adenomyosis.

Understand affection

What is adenomyosis

Adenomyosis occurs when the glandular cells of the endometrium—the inner lining of the uterus that sheds during each menstrual cycle—migrate and proliferate into the myometrium, the muscular layer of the uterus. These ectopic cells continue to respond to cyclical hormonal signals: they thicken during the luteal phase and bleed during the menstrual phase.

Unlike endometriosis (in which endometrial tissue migrates outside the uterus), in adenomyosis the migration is internal—into the uterine wall. This is why the condition has traditionally been called internal endometriosis or endometriosis interna.

The direct biological consequence: local chronic inflammation, progressive fibrosis of the myometrium, and uterine hypertrophy. The uterus can grow to the size of a 12–16 week pregnancy. Myometrial contractions become disorganized and painful—hence the characteristic severe dysmenorrhea.

Signs and symptoms

Adenomyosis symptoms

Approximately 1 in 3 women with confirmed adenomyosis is asymptomatic. The rest present a spectrum of symptoms that vary in intensity and can be confused with other gynecological conditions.

Severe dysmenorrhea

Severe menstrual pain, usually starting before menstruation and persisting throughout its duration. It may be resistant to standard anti-inflammatory drugs (NSAIDs).

Menorrhagia

Heavy and prolonged menstrual periods (over 7 days), sometimes with clots. It can lead to chronic iron deficiency anemia, fatigue, and decreased quality of life.

Chronic pelvic pain

Pressure or dull pain in the pelvis, also present outside of menstruation. Associated with chronic inflammation of the myometrium and local peripheral neuropathy.

Deep dyspareunia

Pain during deep sexual intercourse, caused by increased uterine sensitivity and pressure exerted on the infiltrated myometrium.

Enlarged uterus

Globular, symmetrically enlarged uterus with increased consistency — palpable upon examination or visible on ultrasound. It may cause a sensation of lower abdominal pressure.

Subfertility

Adenomyosis can affect embryo implantation and endometrial receptivity. Its association with infertility is documented, although the exact mechanism remains under study.

Important: Adenomyosis symptoms overlap significantly with those of uterine fibroids, endometriosis, and polycystic ovary syndrome. Differential diagnosis requires imaging (transvaginal ultrasound or pelvic MRI) and, in some cases, histological confirmation post-hysterectomy.

Differential diagnosis

Adenomyosis vs. Endometriosis

Although they have similar biological mechanisms and frequently co-exist, the two conditions differ in terms of location, diagnostic methods, and impact on fertility.

Feature: Location

Adenomyosis: Myometrium (uterine wall)

Endometriosis: Outside the uterus, ovary, peritoneum, intestine

Feature: Imaging diagnosis

Adenomyosis: Transvaginal ultrasound, pelvic MRI

Endometriosis: Diagnostic laparoscopy (gold standard), MRI

Feature: Histological confirmation

Adenomyosis: Requires hysterectomy or myometrial biopsy

Endometriosis: Laparoscopic biopsy of lesions

Feature: Typical age

Adenomyosis: 35–50 years (more common perimenopausally)

Endometriosis: 20–40 years (often onset in adolescence)

Feature: Uterine impact

Adenomyosis: Globular, diffusely enlarged uterus

Endometriosis: Fixed uterus, adhesions; variable size

Characteristic: Typical pain

Adenomyosis: Severe dysmenorrhea + chronic pelvic pressure

Endometriosis: Dysmenorrhea + painful defecation + dyspareunia

Feature: Response to menopause

Adenomyosis: Frequent regression at natural menopause

Endometriosis: May persist post-menopause

Feature: Inflammatory mechanisms

Adenomyosis: IL-6, TNF-α, COX-2 → myometrial inflammation

Endometriosis: IL-6, TNF-α, VEGF → peritoneal inflammation

Sources: ESHRE Endometriosis Guideline 2022; Chapron et al., Nature Reviews Disease Primers, 2019; Gordts et al., Human Reproduction Update, 2018.
Note: ~50% of women with endometriosis also have concurrent adenomyosis. Treatment must address both conditions. Read the complete guide on endometriosis →

Etiology

Causes and risk factors

The exact cause of adenomyosis is not fully understood. Current research supports several hypotheses, which are likely complementary, not exclusive.

01

Endometrial invagination

The most accepted hypothesis: myometrial trauma (childbirth, curettage, cesarean sections) facilitates the migration of endometrial cells deep into the myometrium through fissures in the junctional zone.

02

Cellular metaplasia

Myometrial stem cells can undergo metaplasia — transformation into endometrial-like cells — under the influence of estrogen and local inflammatory mediators.

03

Immune dysfunction

The immune system does not efficiently eliminate ectopic cells. NK cells (natural killer) and macrophages have reduced functionality in the uterine microenvironment of women with adenomyosis.

04

Relative hyperestrogenism

Increased local estradiol concentrations and progesterone resistance promote the proliferation and survival of adenomyotic cells.

05

Genetic factors

Family and twin studies suggest a genetic component (estimated heritability 50–57%). Polymorphisms in the ER-α, CYP17A1, and GSTM1 genes are associated with increased risk.

06

Obstetric history

Previous births, cesarean sections, and dilation and curettage increase the risk. Adenomyosis is more common in multiparous women — contrary to classic endometriosis, which frequently affects nulliparous women as well.

Clinical assessment

How adenomyosis is diagnosed

The definitive diagnosis of adenomyosis was, traditionally, possible only histologically (post-hysterectomy). Modern imaging now allows for non-invasive diagnosis with high sensitivity and specificity.

01

Medical history and clinical examination

A history of severe dysmenorrhea, menorrhagia, and a globular uterus felt during a vaginal examination or abdominal palpation raises clinical suspicion. An adenomyotic uterus is typically symmetrical, tender, and has an increased consistency.

02

Transvaginal ultrasound (TVUS)

First-line imaging: accessible, inexpensive, with 72–82% sensitivity and 84–85% specificity (meta-analysis by Meredith et al., 2009). TVUS signs: globular uterus, myometrial asymmetry, subendometrial linear striations, myometrial cysts, irregular junctional zone.

03

Pelvic MRI

Gold standard for preoperative evaluation: sensitivity 77–78%, specificity 87–89%. Allows measurement of junctional zone thickness (JZ >12 mm = suggestive of diffuse adenomyosis). Useful in differentiating uterine fibroids vs. adenomyosis.

04

Myometrial biopsy (invasive procedures)

Histological confirmation remains the gold standard, but it is only necessary in uncertain cases. It can be performed via hysteroscopy with targeted biopsy or laparotomy. Hysterectomy provides complete confirmation, but it is a definitive, irreversible option.

Molecular biology

The 4 biological mechanisms of adenomyosis

Adenomyosis is not caused by a single imbalance — it involves four interconnected biological axes that amplify one another. Effective treatment must address them simultaneously.

Axis 01

Chronic inflammation

IL-6 · TNF-α · NF-κB · COX-2 · PGE₂

Adenomyotic cells continuously produce proinflammatory cytokines (IL-6, TNF-α) that activate NF-κB—the master regulator of inflammation. COX-2 is locally overexpressed, generating prostaglandins that cause muscle spasms, pain, and sustained inflammation. The cycle is self-perpetuating.

Menstrual pain · Myometrial spasm

Axis 02

Pathological angiogenesis

VEGF · HIF-1α · Angiopoietin-2

Ectopic cells express excess VEGF to build their own vascular supply. Pathological neovascularization fuels adenomyoma growth, intensifies bleeding, and contributes to menorrhagia. Angiogenesis inhibition is a therapeutic target of increasing interest.

Menorrhagia · Lesion growth

Axis 03

Oxidative stress

ROS · 8-OHdG · Reduced glutathione · Fe²⁺

Intra-myometrial bleeding releases free iron (Fe²⁺), which generates free radicals through the Fenton reaction. The amplified oxidative stress damages cellular DNA, activates proinflammatory proteins, and reduces endogenous antioxidant capacity (glutathione, SOD). This maintains an environment conducive to proliferation.

DNA damage · Oxidative inflammation

Axis 04

Estrogen metabolism

CYP19A1 · ER-α · 16α-OH estrone · Progesterone resistance

Adenomyotic cells overexpress aromatase (CYP19A1) — they produce estrogen locally, independently of the ovary. Local estradiol supports proliferation, suppresses apoptosis, and induces progesterone resistance.

The 16α-hydroxylation pathway produces estrogenic metabolites with stronger proliferative action than estradiol.

Proliferation · Hormonal treatment resistance

Therapeutic options

Adenomyosis treatment

There is no non-surgical curative treatment for adenomyosis. The available options aim to control symptoms and reduce progression — the choice depends on severity, age, and desire for fertility.

01

Drug treatment

NSAIDs (ibuprofen, naproxen) for mild-to-moderate dysmenorrhea. Combined oral contraceptives and progestins (medroxyprogesterone, norethindrone) reduce endometrial proliferation and bleeding volume. The levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) is recommended by ESHRE for the long-term management of menorrhagia in women who do not wish to become pregnant.

02

GnRH agonists

Leuprolide, nafarelin — induce pharmacological pseudomenopause, reduce uterine volume by 20–30%. Symptomatic effects are significant but reversible. Long-term use is limited by hypoestrogenic effects (bone loss, hot flashes).

03

Conservative surgical treatment

Endometrial ablation, resection of the focal adenomyoma via hysteroscopy or laparotomy. Symptomatic recurrence rates are high (40–60% at 5 years). Recommended for women who wish to preserve their fertility.

04

Hysterectomy

The only definitive curative treatment. Recommended for women with severe adenomyosis who have completed their family planning and do not respond to conservative treatments. Resolves symptoms in 90–95% of cases.

Nutritional support with clinical doses

Formula built on the 4 biological axes

Discover the formula →

Evidence-based nutritional support

The role of the ENDORA™ formula for female hormonal balance

Nutritional supplements do not replace medical treatment for adenomyosis. Current research shows that certain bioactive compounds, at precise clinical doses, may support the modulation of inflammation, oxidative stress, and estrogen metabolism—the central axes involved in adenomyosis.

NAC (N-acetyl-L-cysteine)

600 mg · 99.7% purity

Glutathione precursor — the most important endogenous antioxidant. It neutralizes free radicals generated by intra-myometrial bleeding.

Axis 3 — Oxidative stress

Boswellia serrata (≥15% AKBBA)

180 mg · AKBBA 15.9%

Boswellic acids — especially AKBBA — are documented inhibitors of 5-LOX (5-lipoxygenase) and the NF-κB pathway. They block the production of proinflammatory leukotrienes without the gastric side effects of NSAIDs.

Axis 1 — Inflammation

DIM (3,3'-Diindolylmethane)

100 mg · 99.2% purity

Primary estrogen metabolism modulator: redirects estrogen metabolism toward the 2-hydroxylation pathway (antiproliferative metabolites) and reduces the 16α-OHE1 pathway (proliferative metabolites). Indirectly supports the rebalancing of the estrogen/progesterone ratio.

Axis 4 — Estrogen metabolism

Micronized trans-resveratrol

80 mg · 99.3% purity

Dual-action polyphenol: antioxidant (SIRT1, Nrf2 activation) and anti-angiogenic (VEGF inhibition). Micronized form increases bioavailability by 3–4×.

Axis 2 — Angiogenesis · Axis 3 — Oxidative

PAM™ Complex (EGCG + Apigenin + Luteolin)

230 mg total · origin Japan

Patented polyphenolic complex with modulating angiogenic action. EGCG 130mg inhibits VEGF and NF-κB activation; Apigenin 50mg and Luteolin 50mg potentiate the anti-inflammatory effect and reduce ectopic cell proliferation through selective apoptosis induction.

Axis 1 + Axis 2 — Inflammation and Angiogenesis

Zinc + Vitamin D3

Zinc 10mg · Vit D3 2000 IU

Zinc supports immune function and NK cell activity — both of which are reduced in adenomyosis. Vitamin D3 at 2000 IU/day reduces the expression of proinflammatory cytokines and regulates progesterone receptors. D3 deficiency is common in endometriosis and adenomyosis.

Immunomodulation · Hormonal regulation

All 9 ingredients are confirmed by a Certificate of Analysis (CoA Batch END-0326-A, Science of Life Pharma, GMP · ISO 22000). Read the full formula analysis →

Evidence base

92% · 78% · 61%

Fertility and pregnancy

Adenomyosis and pregnancy — what the studies say

Adenomyosis affects uterine receptivity and can reduce conception rates, but it does not make pregnancy impossible. Understanding the mechanisms involved helps in choosing the best preconception treatment options.

Quick answer — adenomyosis and pregnancy

Adenomyosis can reduce fertility by affecting uterine contractility and endometrial receptivity. Women with adenomyosis have IVF success rates 15–30% lower compared to those without the condition. Preconception treatment (hormonal or nutritional) may improve implantation rates in some studies.

How does adenomyosis affect fertility? The main mechanisms are: (1) altered uterine contractility — the adenomyotic myometrium has disorganized contractions that interfere with sperm transport and embryo implantation; (2) endometrial receptivity dysfunction — the expression of integrins and receptivity factors (LIF, HOXA10) is reduced in women with adenomyosis; (3) chronic inflammation — the hyperestrogenic and pro-inflammatory endometrial microenvironment is unfavorable for implantation; (4) increased oxidative stress — DNA damage to endometrial cells affects embryo quality and survival.

Adenomyosis and IVF: Published meta-analyses (Vercellini et al., 2014; Maheshwari et al., 2012) show that the presence of adenomyosis in women undergoing IVF protocols is associated with lower implantation rates (OR 0.68) and lower clinical pregnancy rates. However, pregnancy remains possible — especially in mild or focal forms. Treatment of adenomyosis before IVF (GnRH agonists, conservative surgery) has shown improvements in reproductive success rates in some prospective studies.

Spontaneous pregnancy with adenomyosis: Women with mild-to-moderate adenomyosis can conceive spontaneously. Associated obstetric risks include: miscarriage (OR 2.12), preterm birth (OR 1.99), and intrauterine growth restriction — which is why pregnancy follow-up must be careful, with frequent ultrasound evaluation.

15–30%

Reduction in IVF success rates in women with adenomyosis compared to those without the condition (Vercellini et al., Human Reproduction Update, 2014)

OR 2.12

Increased risk of miscarriage in women with adenomyosis compared to those without (meta-analysis by Maheshwari et al., 2012)

~50%

Among women with endometriosis, some also present with concurrent adenomyosis — both conditions must be evaluated before planning a pregnancy

Preconception nutritional support: Research suggests that reducing chronic inflammation and oxidative stress may improve the endometrial microenvironment. Compounds such as NAC (N-acetyl-L-cysteine) — a glutathione precursor — and DIM — an estrogen metabolism modulator — target biological axes involved in uterine dysfunction in adenomyosis. These effects have mechanistic bases documented in peer-reviewed literature, even though randomized clinical trials specific to fertility and adenomyosis remain limited. Read the full analysis of the ENDORA™ formula →

Important note: If you are planning a pregnancy and have been diagnosed with adenomyosis, consult a Reproductive Endocrinology and Infertility (REI) specialist before making any therapeutic decisions. Nutritional supplements do not replace medical evaluation or fertility protocols. Contact us if you have any questions →

Sources: Vercellini P et al. Human Reproduction Update 2014 · Maheshwari A et al. Human Reproduction 2012 · Buggio L et al. Reproductive Sciences 2017

Frequently Asked Questions

Questions about adenomyosis

Does adenomyosis disappear after menopause?

Generally, yes. Adenomyosis is an estrogen-dependent condition. During natural menopause, as ovarian estrogen production declines, adenomyotic cells regress and the uterus gradually shrinks. Most women with adenomyosis become asymptomatic within 1–2 years post-menopause.

Exception: hormone replacement therapy (HRT) with high doses of estrogen can reactivate symptoms. Discuss the choice of HRT type and dosage with your gynecologist if you have a history of adenomyosis.
Can adenomyosis cause infertility?

Adenomyosis is associated with reduced conception and implantation rates, but direct causality is not fully established. Proposed mechanisms include: altered uterine contractility, endometrial receptivity dysfunction, chronic inflammation, and changes in the endometrial microenvironment.

Published studies show that women with adenomyosis have lower IVF success rates (approximately 15–30% lower compared to women without adenomyosis). Treatment of adenomyosis (hormones, conservative surgery) improves reproductive success rates in some studies.
Is adenomyosis the same as endometriosis?

No — they are distinct, albeit related, conditions. The essential difference is the location: in adenomyosis, endometrial tissue migrates internally, into the uterine wall (myometrium). In endometriosis, the migration is external — ovaries, peritoneum, bowel, bladder.

However, the biological mechanisms overlap significantly (inflammation, angiogenesis, estrogen metabolism), and approximately 50% of women with endometriosis also have concurrent adenomyosis. Many treatments are common or complementary. Complete guide to endometriosis →
Can adenomyosis be diagnosed without surgery?

Yes, in the vast majority of cases. Transvaginal ultrasound (TVUS) performed by a specialist experienced in uterine pathology has a sensitivity of 72–82% for adenomyosis. Pelvic MRI is more accurate (sensitivity 77–78%, specificity 87–89%) and is preferred for complex preoperative evaluation.

A definitive histological diagnosis (myometrial biopsy or examination of the hysterectomy specimen) remains the gold standard, but it is not necessary in all cases to initiate treatment.
How long does treatment for adenomyosis last?

There is no standard duration — it depends on the type of treatment and individual response. Oral contraceptives and progestogens are administered continuously, long-term (years). GnRH agonists are usually limited to 6–12 months due to adverse effects.

Nutritional support with bioactive compounds, when chosen, is recommended as a continuous protocol for a minimum of 90 days to allow for the accumulation of biological effects (anti-inflammatory, antioxidant, estrogenic modulation) — with subsequent reevaluation.
Does diet influence adenomyosis?

Direct evidence for adenomyosis is limited, but studies on endometriosis (similar mechanisms) suggest that an anti-inflammatory diet can reduce symptom intensity. A diet rich in omega-3 fatty acids (oily fish, walnuts, flax), cruciferous vegetables (broccoli, cauliflower—which contain DIM precursors), berries (polyphenols), and low in trans fats and refined sugar reduces circulating inflammatory mediators.

Reducing the consumption of processed animal products (which may increase estrogenic load) and avoiding endocrine disruptors (BPA plastic, pesticides) is recommended by nutritional guidelines for estrogen-dependent gynecological conditions.
Can adenomyosis become cancerous?

Adenomyosis is a benign condition. The risk of malignant transformation (uterine adenosarcoma) is extremely rare—estimated at less than 1% of cases in specialized literature—and represents an incidental association rather than a direct transformation.

If you experience new or atypical symptoms, or rapid uterine enlargement following previous stabilization, consult your gynecologist for an imaging reevaluation.

ENDORA™ formula

9 ingredients. 4 biological axes. One single protocol for female hormonal balance.

9 ingredients with clinically confirmed CoA dosages. A 90-day protocol that simultaneously addresses inflammation, oxidative stress, angiogenesis, and estrogen metabolism.

Adenomyosis is a chronic condition — every cycle counts. The 90-day protocol works cumulatively.

 Order ENDORA™ → Read the full formula

30-day warranty | 24h delivery | From 7.47 RON/day | Confirmed CoA · GMP · ISO 22000

Bibliographic references

  1. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666–682. doi:10.1038/s41574-019-0245-z — PMID 31488888
  2. Gordts S, Grimbizis G, Campo R. Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. Fertil Steril. 2018;109(3):380–388. doi:10.1016/j.fertnstert.2018.01.006 — PMID 29566850
  3. Meredith SM, Sanchez-Ramos L, Kaunitz AM. Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and metaanalysis. Am J Obstet Gynecol. 2009;201(1):107.e1–6. — PMID 19398089
  4. Vannuccini S, Tosti C, Carmona F, Huang SJ, Chapron C, Guo SW, Petraglia F. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online. 2017;35(5):592–601. — PMID 28693952
  5. Becker CM, Bokor A, Heikinheimo O et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. doi:10.1093/hropen/hoac009 — PMID 35350465
  6. Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum Reprod Update. 2014;20(3):386–402. — PMID 24140719
  7. Kvaskoff M, Mu F, Terry KL, Harris HR, Poole EM, Farland L, Missmer SA. Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update. 2015;21(4):500–516. — PMID 25765863

Medical disclaimer: This content is for informational and educational purposes — it does not constitute medical advice, diagnosis, or treatment. Any therapeutic decision must be made in collaboration with your gynecologist. Nutritional supplements do not replace conventional medical treatment for adenomyosis.